遇见数据集

A Single-Arm, Multicenter, Phase 2 Study of Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

收藏
DataCite Commons2025-10-10 更新2026-05-07 收录
官方服务:

资源简介:

The purpose of this study is to evaluate efficacy and safety of brigatinib in Japanese participants with anaplastic lymphoma kinase (ALK)-positive NSCLC.

提供机构:
Vivli
创建时间:
2025-10-09
二维码
社区交流群
二维码
科研交流群
商业服务